Search

Displaying results 6061 - 6070 of 10000 in total
  1. Drug

    Trichophyton rubrum

    go.drugbank.com/drugs/DB10915
    Approved

    Trichophyton rubrum extract is used in allergenic testing.

  2. Drug

    Cochliobolus lunatus

    go.drugbank.com/drugs/DB10933
    Approved

    Cochliobolus lunatus extract is used in allergenic testing.

  3. Drug

    Haematonectria haematococca

    go.drugbank.com/drugs/DB10934
    Approved

    Haematonectria haematococca extract is used in allergenic testing.

  4. Drug

    Neurospora sitophila

    go.drugbank.com/drugs/DB10969
    Approved

    Neurospora sitophila extract is used in allergenic testing.

  5. Drug

    Nordazepam

    go.drugbank.com/drugs/DB14028
    Investigational

    An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.

    Synonyms: N-desmethyldiazepam
  6. Drug

    Pentafluoropropane

    go.drugbank.com/drugs/DB13117
    ApprovedWithdrawn

    Pentafluoropropane is under investigation in clinical trial NCT01673061 (Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage).

  7. Drug

    Hyaluronic acid (non-animal stabilized)

    go.drugbank.com/drugs/DB19175
    ApprovedWithdrawn

    Hyaluronic acid (non-animal stabilized) is under investigation in clinical trial NCT03460158 (Prospective Evaluation of Facial Cosmetic Procedures).

  8. Drug

    Nialamide

    go.drugbank.com/drugs/DB04820
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.

    Synonyms: N-Isonicotinoyl-N'(beta-N-benzylcarboxamidoethyl)hydrazine, N-(2-(Benzylcarbamyl)ethylamino)isonicotinamide
  9. Drug

    Sparsomycin

    go.drugbank.com/drugs/DB04222
    Experimental

    An antitumor antibiotic produced by Streptomyces sparsogenes. It inhibits protein synthesis in 70S and 80S ribosomal systems. [PubChem]

  10. Drug

    Dexloxiglumide

    go.drugbank.com/drugs/DB04856
    Investigational

    Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued.